Latest News - Research and Publications

Tuesday, May 23, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications

Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significant…

Read the full story

Friday, May 19, 2017 | Pain & Headache, Research and Publications

Migraine Prevalence Higher in Collegiate Athletes, New Study Finds

New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluate…

Read the full story

Tuesday, May 16, 2017 | Product Launches and Updates, Research and Publications, Stroke & Cerebrovascular

Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Friday, May 12, 2017 | Research and Publications, Stroke & Cerebrovascular

Elevated B2M Levels Tied to Ischemic Stroke Risk in Women

β2-microglobulin (B2M) levels may be an indicator of ischemic stroke risk in women, according to new findings published in Neurology (May 10). Investigators performed a nested case-control study …

Read the full story

Friday, May 12, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results

New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, pati…

Read the full story

Friday, May 05, 2017 | FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications

FDA Greenlights First New Treatment for ALS in More than Two Decades

The FDA has approved Radicava (edaravone, MT Pharma), as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS). Radicava is the first treatment approved for the treatment of A…

Read the full story

Thursday, May 04, 2017 | Neuromuscular & Immune Disorders, Product Launches and Updates, Research and Publications

MS Topography App Launches

A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation th…

Read the full story

Wednesday, May 03, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Product Launches and Updates, Research and Publications

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS Syste…

Read the full story

Friday, April 28, 2017 | Healthcare Trends, Research and Publications, Stroke & Cerebrovascular

AAN 2017 Meeting: Racial and Regional Disparities Identified in Endovascular Care Delivery

Access to endovascular care is significantly impacted by factors such as race, region, and hospital, according to findings presented this week at the American Academy of Neurology (AAN) Annual Meeting…

Read the full story

Wednesday, April 26, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab

New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 …

Read the full story

Wednesday, April 26, 2017 | Movement Disorders, Research and Publications

AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut

Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of…

Read the full story

Tuesday, April 25, 2017 | Epilepsy & Seizure Disorders, Research and Publications

AAN Unveils New Guideline for SUDEP at Annual Meeting

The American Academy of Neurology (AAN) and the American Epilepsy Society (AES) have released a new joint guideline for sudden unexpected death in epilepsy (SUDEP) at the AAN Annual Meeting in Boston.…

Read the full story

Monday, April 24, 2017 | Movement Disorders, Personnel/Company News, Research and Publications

Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS

Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting&…

Read the full story

Monday, April 17, 2017 | Healthcare Trends, Research and Publications, Stroke & Cerebrovascular

Stroke Hospitalization Rates and Risk Factors Increasing in Young Adults

Rates of acute ischemic stroke are increasing in young adults, new findings suggest (JAMA Neurology, April 10). Investigators analyzed stroke hospitalization rates as well as associated risk factors a…

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story
Load More